Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

April 13, 2018: By Jon Swedien

AbbVie has struck a deal with Samsung Bioepis and Biogen that will allow the partners to sell Imraldi—a biosimilar referencing Humira (adalimumab)—in Europe beginning in 2018, and, in exchange, they have agreed to drop a lawsuit challenging Humira’s patent, the companies announced April 5.

Humira is indicated in Europe for chronic non-infectious anterior uveitis.

Under terms of the agreement, AbbVie said it will grant patent licenses for the use and sale of Imraldi in Europe on a country-by-country basis, and the license period will begin in most European Union countries Oct. 16, 2018.

Samsung Bioepis and Biogen will make royalty payments to AbbVie, the companies said.

AbbVie also disclosed the deal will allow Samsung Bioepis to sell its biosimilar in the US beginning June 30, 2023.

The precise terms of the agreements are confidential, the companies said.

In 2017, AbbVie struck a deal with Amgen allowing it to sell its Humira biosimilar in the US beginning in January 2023 in exchange for royalty payments to AbbVie and dropping a patent challenge to Humira.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023